CClinicalTrials.gg
CompletedNCT03320408PARISUpdated Aug 22, 2023

Predicting Aneurysm Growth and Rupture With Longitudinal Biomarkers

An observational study in Abdominal Aortic Aneurysm and Abdominal Aortic Aneurysm, Ruptured, sponsored by Ron Balm. Completed at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-22.

Sponsored by Ron Balm · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
790
Ages
18 Years and older
Sex
All
01

Study summary

First aim: PARIS study

The main aim of the current study is to determine the association between abdominal aortic aneurysm (AAA) progression and the evolution of proteases and cytokines levels.To achieve this aim, we will prospectively collect blood, aortic tissue, patient data, and imaging data. Aortic tissue will only be obtained when patients undergo conventional open repair. The other biomaterials will be collected during regular patient follow-up visits, with a maximum frequency of once per year.

Second aim: Pearl AAA biobank

For future research purposes, a new biobanking infrastructure will be created to collect and store additional blood and urine samples in a biobank. This biobank will be embedded within the infrastructure of the 'Parelsnoer Institute' (PSI) and will be called Pearl AAA. The Pearl AAA will be established in the extension of the PARIS study

Read the detailed description

The PARIS study aims to determine the correlation between AAA progression (growth or rupture) and the evolution of serum levels of proteases and cytokines over time. A repeated measures analysis will be done to use all longitudinal data available.

The Pearl AAA biobank will be established to enable the PARIS study, but also aims to facilitate future research. Such future research should fall under the scientific aims of the Pearl AAA, which are:

  • To gain insight in the pathogenesis of AAA
  • To gain more knowledge in the rupture risk of AAA
  • To evaluate and potentially improve treatment of AAA

The 'Parelsnoer Institute' will facilitate the biobank Pearl AAA with certain aspects such as, but not limited to the following:

  • Standardized operating procedures for the collection and storage of the biosamples across all participating hospitals
  • Information architect to establish a data dictionary in which all variables are defined
  • Standardized procedures for coding of patient data before storage
  • Standardized digital infrastructure to enhance storage of patient data and imaging data
02

Conditions studied

  • Abdominal Aortic Aneurysm
  • Abdominal Aortic Aneurysm, Ruptured

Keywords

  • biobank
  • pathogenesis
  • Aortic Aneurysm
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All adult patients with an abdominal aortic aneurysm who present themselves in the participating hospitals.

Inclusion criteria

  • Adult participant (18 years or older)
  • Participant has an AAA or has previously been treated for an AAA
  • Adequate comprehension of the Dutch language to provide written informed consent

Exclusion criteria

Exclusion Criteria:

  • A patient who is decisionally impaired. The only exception to this are the patients who are decisionally impaired due to the effects of an acute AAA. This particular group is eligible for which a separate recruitment and consent procedure exists.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
790 participants (actual)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Asymptomatic AAA

    These patients will be included while their AAA is asymptomatic and while they are under surveillance by their vascular surgeon.

  • Acute AAA

    These are the patients that are included while they presented in the participating hospitals because either a symptomatic or ruptured AAA. For this group, a different recruitment procedure exists which has been approved by the appropriate medical ethical committee.

  • Repaired AAA

    These patients are included while they already had had AAA repair (both elective and emergency repair).

05

What researchers measure

Primary outcomes

  1. AAA growth

    Growth of abdominal aortic aneurysm, measured on imaging made for clinical purposes

    Time frame: Up to 10 years of follow-up

  2. AAA rupture

    Rupture of an abdominal aortic aneurysm

    Time frame: Up to 10 years of follow-up

  3. Death

    All-cause mortality

    Time frame: Up to 10 years of follow-up

  4. Evolution of serum levels of proteases

    Repeated measurements analysis of serum levels of proteases in cohort of asymptomatic AAAs

    Time frame: a maximum of 1 measurement annually up to 10 years of follow-up

  5. Evolution of serum levels of cytokines

    Repeated measurements analysis of serum levels of cytokines in cohort of asymptomatic AAAs

    Time frame: a maximum of 1 measurement annually up to 10 years of follow-up

  6. Protease levels in aortic tissue

    Protease levels in aortic tissue

    Time frame: If open AAA repair is performed and aortic tissue is collected, protease levels will then be measured. This is a one-time measurement.

  7. Cytokine levels in aortic tissue

    Cytokine levels in aortic tissue

    Time frame: If open AAA repair is performed and aortic tissue is collected, cytokine levels will then be measured. This is a one-time measurement.

Secondary outcomes

  1. Type of complications after AAA repair

    Type of complications using methodology from the Dutch committee of the "Nederlandse Vereniging voor Heelkunde," named the "Landelijke Heelkunde Complicatie Registratie" as found on www.lhcr.nl

    Time frame: Will be measured up to 10 years after AAA repair is performed

  2. Incidence of complications after AAA repair

    Number of complications after abdominal aortic aneurysm repair

    Time frame: Will be measured up to 10 years after AAA repair is performed

06

Study locations

2 sites
  • Leiden University Medical Center (LUMC)
    Leiden, Zuid-Holland 2333ZA, Netherlands
  • Department of Vascular Surgery, Amsterdam UMC, location AMC
    Amsterdam, 1105 AZ, Netherlands
07

References and documents

Publications

  • Jalalzadeh H, Indrakusuma R, Blankensteijn JD, Wisselink W, Yeung KK, Lindeman JHN, Hamming JF, Koelemay MJW, Legemate DA, Balm R. Design and protocol of a comprehensive multicentre biobank for abdominal aortic aneurysms. BMJ Open. 2019 Aug 1;9(8):e028858. doi: 10.1136/bmjopen-2018-028858. PubMed 31375618 ↗

Individual participant data

Plan to share: Yes — Researchers can initiate the procedure to request IPD for research that falls within the scientific scope of the biobank Pearl AAA.

08

Registry details

Key details

Study ID
NCT03320408
Lead sponsor
Ron Balm
Responsible party
Ron Balm (Principal Investigator, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Sponsor-investigator
First posted
Oct 25, 2017
Start date
Oct 4, 2017
Primary completion
Aug 4, 2023
Completion
Aug 4, 2023
Last update
Aug 22, 2023

Study contacts

Ron Balm, MD PhD
principal investigator · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion